Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q86XP0
UPID:
PA24D_HUMAN
Alternative names:
Phospholipase A2 group IVD
Alternative UPACC:
Q86XP0; Q8N176
Background:
Cytosolic phospholipase A2 delta, also known as Phospholipase A2 group IVD, plays a crucial role in cellular processes by selectively hydrolyzing glycerophospholipids at the sn-2 position. It exhibits a preference for linoleic acid, highlighting its specificity in lipid metabolism.
Therapeutic significance:
Understanding the role of Cytosolic phospholipase A2 delta could open doors to potential therapeutic strategies. Its precise function in lipid metabolism makes it an intriguing target for addressing disorders related to lipid dysregulation.